Abiopharma

AB Science announces today the successful completion of capital increases of a total gross amount of EUR 14.2 million

Class action lawsuit against Bat regarding incorrect interpretation of the definition of the insurance event of acute heart attack

Investor Presentation - Strategic move to increase the Company’s holdings in Doral LLC

Silicon Motion Unveils MonTitan™ SSD Reference Design Kit for AI Infrastructure

Supplementary report – completion of the transaction for the acquisition of Escofi

MindMaze Therapeutics Completes Organizational Simplification and Provides Update on Neuro.io Equity Financing

Private placement of 232,000 shares to the management company

Capital market presentation -H1-2026

Increase of the Company’s holdings in Doral LLC to approximately 53%; investors call on 10.8.26 at 10:30

Dividend of 91.18832 agorot per share, ex-date 29.10.26, payment 10.11.26